Loading clinical trials...
Loading clinical trials...
LIMIT Melanoma: (Lysosomal Inhibition + Melanoma ImmunoTherapy) A Phase 1/2 Open Label Trial of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Patients With Advanced Melanoma
Conditions
Interventions
Nivolumab
Hydroxychloroquine
+1 more
Locations
1
United States
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
October 21, 2020
Primary Completion Date
October 30, 2025
Completion Date
October 30, 2025
Last Updated
July 8, 2025
NCT02621021
NCT07177937
NCT03050268
NCT05969860
NCT03340506
NCT04693377
Lead Sponsor
Ravi Amaravadi, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions